Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan B Sandler

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Oncology (Williston Park, N.Y.)|June 2, 2006
Nondermatologic adverse events associated with anti-EGFR therapyAlan B Sandler
Seminars in Oncology|March 14, 2003
Chemotherapy for small cell lung cancerAlan B Sandler
Clinical Lung Cancer|December 4, 2003
Molecular targeted agents in non-small-cell lung cancerAlan B Sandler
Seminars in Oncology|February 7, 2006
Targeting angiogenesis in lung cancerAlan B Sandler
Clinical Lung Cancer|February 3, 2012
Beyond bevacizumab: antiangiogenic agentsShane Rogosin, Alan B Sandler
Proceedings of the American Thoracic Society|April 8, 2009
Angiogenesis in the treatment of non-small cell lung cancerLeora Horn, Alan B Sandler
The Oncologist|June 24, 2006
Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selectionSuresh Ramalingam, Alan B Sandler
Clinical Lung Cancer|April 14, 2009
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancerLeora Horn, Alan B Sandler
The Oncologist|January 25, 2013
The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agentsKyle W Robinson, Alan B Sandler
Lung Cancer (Amsterdam, Netherlands)|July 18, 2003
The importance of the eicosanoid pathway in lung cancerJanessa J Laskin, Alan B Sandler
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Oncology (Williston Park, N.Y.)|June 2, 2006
Nondermatologic adverse events associated with anti-EGFR therapyAlan B Sandler
Seminars in Oncology|March 14, 2003
Chemotherapy for small cell lung cancerAlan B Sandler
Clinical Lung Cancer|December 4, 2003
Molecular targeted agents in non-small-cell lung cancerAlan B Sandler
Seminars in Oncology|February 7, 2006
Targeting angiogenesis in lung cancerAlan B Sandler
Clinical Lung Cancer|February 3, 2012
Beyond bevacizumab: antiangiogenic agentsShane Rogosin, Alan B Sandler
Proceedings of the American Thoracic Society|April 8, 2009
Angiogenesis in the treatment of non-small cell lung cancerLeora Horn, Alan B Sandler
The Oncologist|June 24, 2006
Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selectionSuresh Ramalingam, Alan B Sandler
Clinical Lung Cancer|April 14, 2009
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancerLeora Horn, Alan B Sandler
The Oncologist|January 25, 2013
The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agentsKyle W Robinson, Alan B Sandler
Lung Cancer (Amsterdam, Netherlands)|July 18, 2003
The importance of the eicosanoid pathway in lung cancerJanessa J Laskin, Alan B Sandler
Pageof 7